U.S. Judge Frees Gilead from $200M in Damages to Merck

Jun 14, 2016

Reuters

U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck deceptively used confidential information from Pharmasset

Reuters reports that a U.S. judge cited a pattern of misconduct by Merck & Co, which released Gilead Sciences from paying any damages for infringing Merck's patents on its hepatitis C treatments, Sovaldi and Harvoni.

This ruling follows a March 24th order from a federal jury that said Gilead had to pay $200M in damages to Merck.

Read the Reuters story